Fact based stock research
Takeda Pharmaceutical (TSE:4502)


Takeda Pharmaceutical stock research in summary

takeda.com


Takeda Pharmaceutical shares are cheaper than other comparable stocks. They are good value and show above average growth, but are riskily financed. We recommend evaluating if the future of the company Takeda Pharmaceutical is really as difficult as the low price of the shares suggests. If you believe that the future of the company is market-typical or even better, then this would be an argument for a share purchase.


Latest Obermatt Ranks


Country Japan
Industry Pharmaceuticals
Index Nikkei 225, TOPIX 100
Size class XX-Large

April 19, 2019. Stock data may be delayed. Login to get the most recent research.




Research History: Takeda Pharmaceutical

RESEARCH HISTORY 2016 2017 2018 2019
VALUE
VALUE
GROWTH
GROWTH
SAFETY
SAFETY
COMBINED
COMBINED

Last update of Combined Rank: 19-Apr-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Takeda Pharmaceutical is in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2016 2017 2018 2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)
DIVIDEND YIELD
DIVIDEND YIELD
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE

Last update of Value Rank: 19-Apr-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Takeda Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2016 2017 2018 2019
REVENUE GROWTH
REVENUE GROWTH
PROFIT GROWTH
PROFIT GROWTH
STOCK RETURNS
STOCK RETURNS
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH

Financial reporting date of Growth Rank: 31-Dec-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Takeda Pharmaceutical.


Safety Metrics in Detail

SAFETY METRICS 2016 2017 2018 2019
LEVERAGE
LEVERAGE
REFINANCING
REFINANCING
LIQUIDITY
LIQUIDITY
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY

Financial reporting date of Safety Rank: 31-Dec-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Takeda Pharmaceutical and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Takeda Pharmaceutical from April 19, 2019.


We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.

Register for
stock tips now


Stock investing made easy